FDA Policy for REMS Reqmts during COVID-19
Health Care, Pharma Industry, Strategic Planning
FDA is issuing this guidance to communicate its temporary policy for certain risk evaluation and mitigation strategies (REMS) requirements for the duration of the coronavirus pandemic public health emergency.
Read the Policy now
Related Education Resources.
All ResourcesPATIENT Receptivity to Direct-to-Patient Shipment in Clinical Trials - a GCSG sponsored study
Topic: Direct-to-Patient
White Paper
Members
European Roadmap to Lift COVID-19 Containment
Topics: Health Care, Strategic Planning
White Paper
Free
Nat'l Coronavirus Response - Road Map to Reopening
Topics: Health Care, Strategic Planning
Report
Free
